Similar articles

• Risk factors for persistent ductus arteriosus patency during indomethacin treatment.

  Chorne N, Jegatheesan P, Lin E, Shi R, Clyman RI. Chorne N, et al. J Pediatr. 2007 Dec;151(6):629-34. doi: 10.1016/j.jpeds.2007.05.007. Epub 2007 Aug 6. J Pediatr. 2007. PMID: 18035143
• Cardiovascular pharmacological therapy in children--a review. Part 4: Manipulation of vascular resistance and patent ductus arteriosus.

  Chan KY, Yip WC, Tay JS. Chan KY, et al. J Singapore Paediatr Soc. 1989;31(1-2):26-31. J Singapore Paediatr Soc. 1989. PMID: 2671493 Review. No abstract available.
• Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study.

  Yanagi RM, Wilson A, Newfeld EA, Aziz KU, Hunt CE. Yanagi RM, et al. Pediatrics. 1981 May;67(5):647-52. Pediatrics. 1981. PMID: 7019841 Clinical Trial.
• The pharmacologic closure of the patent ductus arteriosus.

  Van Overmeire B, Chemtob S. Van Overmeire B, et al. Semin Fetal Neonatal Med. 2005 Apr;10(2):177-84. doi: 10.1016/j.siny.2004.10.003. Epub 2004 Dec 15. Semin Fetal Neonatal Med. 2005. PMID: 15701582 Review.
• Medical treatment leads to closure of patent ductus arteriosus.

  Danilevicius Z. Danilevicius Z. JAMA. 1977 May 23;237(21):2326. JAMA. 1977. PMID: 576928 No abstract available.